Vmbook Online ordering
Transition Therapeutics Inc
Transition Therapeutics, Inc. was a biotechnology company focused on developing therapeutics for cancer, metabolic, and inflammatory diseases. The company was founded in 1998 and was headquartered in Toronto, Canada. However, it was delisted from the NASDAQ stock exchange in 2017.
The company's leading drug candidate was TransCon-cizumab, a long-acting thyroid cancer drug. The drug was designed to treat thyroid cancer patients who require lifelong thyroid hormone replacement therapy. TransCon-cizumab combines Transition's thyroid hormone receptor modulator (TRM) technology with cizumab, a monoclonal antibody that binds to TSH. The drug's Phase 3 clinical trials for treating hypothyroidism did not meet their primary endpoints.
Transition Therapeutics' pipeline also included the Metarrison family, which included drugs such as TT401, TT402, and TT500. These drugs aimed to treat various metabolic and inflammatory disorders.
In 2014, the company signed a partnership agreement with Zosano Pharma, giving them the right to acquire Transition Therapeutics' rights to develop and commercialize TransCon-cizumab worldwide, except for Greater China. Transition Therapeutics has also partnered with Innovax (Beijing) Biotech Co., a subsidiary of CJ HealthCare, granting them an exclusive license to develop and commercialize TransCon-cizumab in the Greater China territory.
These partnerships helped transition Therapeutics focus on development activities and further establish its technology. However, the company faced significant challenges in advancing its candidates through human clinical trials, leading to disappointing clinical trial results in 2015. Ultimately, Transition Therapeutics was delisted from the NASDAQ stock exchange in 2017.
While Transition Therapeutics appears to be inactive, its research and technology continue influencing the industry. The company's innovative approach to developing therapeutics for various diseases may pave the way for future advancements in healthcare.